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Aims: The study investigated the antidepressant-like effect and acute toxicity of 4-phenyl-1-(phenylselanylmethyl)-
1,2,3-triazole (Se-TZ), an organoselenium-containing heterocycle compound in mice.
Main methods: The antidepressant-like effect of Se-TZ (1–50 mg/kg) and its mechanism of action, was analyzed in
the tail suspension test (TST) in male C57BL/6J mice. Additionally, the levels of the monoamines and their metabo-
lites in cerebral cortex andhippocampuswere analyzed byhigh-performance liquid chromatography. To investigate
the potential acute toxicity caused by Se-TZ, the mice received a single oral dose of Se-TZ (1–50 mg/kg), and after
72 h were performed the assays.
Key ﬁndings: The Se-TZ (5-50 mg/kg) signiﬁcantly reduced immobility time in TST without altering locomotor and
exploratory activities. The antidepressant-like effect of Se-TZ (25 mg/kg) in the TSTwasprevented bypre-treatment
of mice with SCH23390, sulpiride and methysergide, but not with prazosin, yohimbine and propranolol. Se-TZ, in-
creased monoamine neurotransmitters dopamine and serotonin levels in the cerebral cortex and hippocampus,
whereas norepinephrine turnover was not changed. This study also demonstrated that the Se-TZ, did not cause
the acute toxicity in biochemical markers hepatic and renal investigated. The results evidenced that exposure to
Se-TZ caused a signiﬁcant increase in the catalase (CAT) activity in the cerebral cortex and hippocampus, however
the glutathione S-transferase (GST) activity increased only in the cerebral cortex.
Signiﬁcance: These results suggest that Se-TZ demonstrated antidepressant-like effect, mediated via the central do-
paminergic and serotoninergic neurotransmitter systems which may be of interest as a therapeutic agent for the
treatment of depressive disorders.© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license.Introduction
Depression is one of the most prevalent, serious, recurrent, incapac-
itating and costly psychopathologies worldwide, being characterized by
altered mood and cognitive functions, and recurrent thoughts of death
or suicide with a lifetime incidence of 15–25% and is associated with a
signiﬁcant impairment in social and occupational functioning as well
as a reduced quality of life (Kessler and Wang, 2009; Paykel, 2006).r (C.R. Jesse),
. Open access under CC BY-NC-ND liceAccording to theWorld Health Organization, unipolar depressive disor-
ders were ranked as the third leading cause of the global burden of dis-
ease in 2004 and will move into the ﬁrst place by 2030 (WHO, 2011).
It is well known that monoamine neurotransmitters such as seroto-
nin, noradrenaline and dopamine in the central nervous system play a
key role in the pathophysiology of depression (Elhwuegi, 2004). Evi-
dence suggests that alterations in monoaminergic systems are associat-
ed with the mechanisms of action underlying the favorable therapeutic
activity of antidepressant drugs. Effective antidepressant treatments
normalize the disturbed monoaminergic systems which are assumed
to be responsible for the clinical features of depression (Sartorius
et al., 2007).
Although themechanism provoking depression has not been clearly
elucidated oxidative stress, via free radical production, may play an im-
portant role in its pathophysiology (Ng et al., 2008). Under physiological
conditions there is a balance between oxidative and antioxidativense.
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these systems in favor of the former and has been implicated in the
pathophysiology of several neuropsychiatric diseases, including major
depressive disorder (MDD) (Behr et al., 2012). In particular, a number
of oxidative disturbances with a decrease in antioxidant enzyme activi-
ties in patients diagnosed with depression have been reported, includ-
ing enhanced oxidative damage, while the antidepressant treatment
ameliorated this effect (Ng et al., 2008; Sarandol et al., 2007). Based
on increasing importance in the ﬁeld of synthesis of heterocyclic com-
pounds, a series of researchers has been concentrated on development
of heterocyclic compounds having therapeutic high potential toward a
variety of human diseases (Alves et al., 2008; Seus et al., 2012). Further-
more, studies have demonstrated the role of selenium in mood disor-
ders (Hawkes and Hornbostel, 1996; Sher, 2007). In this context,
selenium-containing heterocycles are of considerable biochemical and
pharmacological relevance (Ninomiya et al., 2011), among currently
identiﬁed stands the ebselen (2-phenyl-1,2-benzilsoselenazol-3 (2H)-
one) which displays catalytic activity and antioxidant properties similar
to glutathione peroxidase (Satoh et al., 2004) and antidepressant-like
effect (Posser et al., 2009). Other organic compounds (selenium-
containing heterocycles) are also beingwidely studied andhave numer-
ous pharmacological properties, including antidepressant-like effects
(Gai et al., 2012; Gay et al., 2010).
Thus, the aims of the present study were to evaluate the
antidepressant-like effect of Se-TZ in mice, as well as, analyze its acute
toxicity. Additionally, for understanding the antidepressant mecha-
nism, this study investigated the possible involvement of the noradren-
ergic, dopaminergic and serotonergic systems in the antidepressant-
like effect of the Se-TZ in the tail suspension test (TST).We also examine
levels of the monoaminergic neurotransmitter and their metabolite
changes in speciﬁc brain regions (cerebral cortex and hippocampus)
after administration of the Se-TZ.
Materials and methods
Animals
The experiments were conducted using male C57BL/6J mice
(25–30 g) maintained at 22–25 °C with free access to water and food,
under a 12:12 h light/dark cycle (lights on at 07:00 h). All manipula-
tions were carried out between 09:00 a.m. and 04:00 p.m., with each
animal used only once. All procedures in this study were performed in
accordance with the National Institute of Health Guide for the Care
and Use of Laboratory Animals. The experiments were performed
after approval of the protocol by the Institutional Ethics Committee
(CEUA/UNIPAMPA) under number 027/2012, and all efforts were
made to minimize animals suffering and to reduce the number of ani-
mals used in the experiments.
Chemicals
4-Phenyl-1-(phenylselanylmethyl)-1,2,3-triazole (Se-TZ; Fig. 1)
was prepared and characterized as previously described (Seus et al.,
2012). Analysis of the 1H NMR and 13C NMR spectra showed analyticalN N
N
Se
Fig. 1. Chemical structure of 4-phenyl-1-(phenylselanylmethyl)-1,2,3-triazole.and spectroscopic data in full agreement with its assigned structure.
The chemical purity of Se-TZ (99.9%) was determined by GC/MS and
13C NMR analysis. The following drugs were used: ﬂuoxetine, imipra-
mine, prazosin, yohimbine, propranolol, SCH 23390, sulpiride, and
methysergide (Sigma Chemical Co., USA). All drugs were dissolved in
saline 0.9%, except Se-TZ that was dissolved in canola oil with 10% of di-
methyl sulfoxide (DMSO) for the in vivo experiments. Mice received all
drugs in a constant volume of 10 ml/kg body weight. Appropriate
vehicle-treated groupswere also assessed simultaneously. The chemical
standards used in HPLC including noradrenaline and its metabolite 4-
hydroxy-3-methoxyphenylglycol (MHPG), dopamine and its metabo-
lites, 3,4-dihydroxyphenyla-cetic acid (DOPAC), serotonin and its
metabolite 5-hydroxyindoleacetic acid (5-HIAA), were purchased from
Sigma-Aldrich Corporation (St. Louis, MO, USA) and were dissolved in
the mobile phase.
Behavioral testing
Tail suspension test (TST)
The total duration of immobility induced by tail suspension was
measured according to the method described by Steru et al. (1985).
Mice both acoustically and visually isolated were suspended 50 cm
above the ﬂoor by adhesive tape placed approximately 1 cm from the
tip of the tail. Immobility time was recorded during a 6-min period
(Jesse et al., 2009).
For the time–course curve, mice were submitted to the TST 30, 60,
120 and 240 min after the administration of Se-TZ (50 mg/kg, p.o.) or
vehicle (10 ml/kg, p.o.). For the dose–response curve,micewere treated
with Se-TZ (1, 5, 25 and 50 mg/kg, p.o.), or vehicle 30 min before the
TST. Fluoxetine (32 mg/kg, p.o.) and imipramine (15 mg/kg, p.o.),
were used as positive controls and they were administered 30 min be-
fore the TST.
These experiments were designed to verify the possible involve-
ment of noradrenergic, serotonergic and dopaminergic systems in
the antidepressant-like effect of Se-TZ. For this, mice received a sin-
gle injection of prazosin (1 mg/kg, i.p., an α1-adrenoceptor antago-
nist), yohimbine (1 mg/kg, i.p., an α2-adrenoceptor antagonist),
propranolol (2 mg/kg, i.p., a β-adrenoceptor antagonist), SCH23390
(0.05 mg/kg, s.c., a selective dopamine D1 receptor antagonist),
sulpiride (50 mg/kg, i.p., a selective dopamine D2 receptor antago-
nist) and methysergide (2 mg/kg, s.c., a non-selective serotoninergic
receptor antagonist) or saline (10 ml/kg) 30 min before the admin-
istration of Se-TZ (25 mg/kg, p.o.) or vehicle. Thirty minutes after
treatment with Se-TZ or vehicle, the mice were submitted to the
TST. All doses of antagonists used in this workwere chosen according
to previously published data (Jesse et al., 2010; Savegnago et al.,
2007; Villarinho et al., 2012).
Open-ﬁeld test (OFT)
To assess the possible effects of Se-TZ on locomotor activity, mice
were evaluated in the open-ﬁeld test (OFT), as described by Walsh
and Cummins (1976). The open-ﬁeld was made of polywood and
surrounded by walls 30 cm in height. The ﬂoor of the open-ﬁeld,
45 cm in length and 45 cm in width, was divided by masking tape
markers into 09 squares (3 rows of 3). Each animal was placed individ-
ually at the center of the apparatus and observed for 6 min to record the
locomotor (number of segments crossed with the four paws) and ex-
ploratory activities (expressed by the number of time rearing on the
hind limbs). Mice were treated with Se-TZ (1, 5, 25 and 50 mg/kg,
p.o.), or vehicle 30 min before the TST. Another groups of mice were
pretreated with prazosin (1 mg/kg, i.p.) or yohimbine (1 mg/kg, i.p.)
or propranolol (2 mg/kg, i.p.) or SCH23390 (0.05 mg/kg, s.c.) or
sulpiride (50 mg/kg, i.p.) or methysergide (2 mg/kg, s.c.) or saline
(10 ml/kg). Thirty minutes after this treatment or pretreatment, the
mice were submitted to the OFT.
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Mice were euthanized by cervical dislocation 2 h after the admin-
istration of Se-TZ (25 mg/kg, p.o.) or vehicle (10 ml/kg, p.o.). The
brains were excised, and the cerebral cortex and hippocampus
were immediately separated and stored at −80 °C until analyzed
by high-performance liquid chromatography (HPLC). The levels of
themonoamines noradrenaline, dopamine, serotonin, and their metab-
olites 4-hydroxy-3-methoxyphenylglycol (MHPG), 3,4-dihydroxyphe-
nylacetic acid (DOPAC) and hydroxyindole acetic acid (5-HIAA), were
assayed as described by Ferraz et al. (2002), using high performance liq-
uid chromatography (HPLC) with electrochemical detection. The mo-
bile phase, used at a ﬂow rate of 0.8 ml/min, consisted of 0.02 M
phosphate/citrate buffer and 90/10methanol (v/v), 0.12 mMNa2EDTA,
and 0.0556% heptane sulphonic acid as ion pair. The pHwas adjusted to
2.64 with H3PO4 at 22 °C. A 5-μm (220 × 4.6) Spheri-5 RP-18 column
from Brownlee Laboratory was used. Electrochemical detection of
monoamines was performed with a Shimadzu L-ECD-6A electrochemi-
cal detector with a potential of 0.75 V. The peak area of the internal
standard (DHBA) was used to quantify the sample peaks. The tissue
levels were expressed in ng/g tissue.
Acute toxicity and biochemical parameters
To investigate the potential acute toxicity and changes of biochemi-
cal parameters caused by Se-TZ, the mice received a single oral dose of
Se-TZ (1, 5, 25 and 50 mg/kg) or vehicle (10 ml/kg). After drug admin-
istration, animals were observed for up to 72 h. After this time, the an-
imals were anesthetized for the blood collection by heart puncture into
heparin containing tubes. Plasma was obtained by centrifugation at
2000 g for 10 min and used for the acute toxicity assays. The liver, kid-
ney, cerebral cortex and hippocampuswere quickly removed, placed on
ice, and homogenized in cold 50 mMTris–HCl, pH 7.4 (liver and kidney:
1/10 w/v; and cerebral cortex and hippocampus 1/5, w/v). The homog-
enate was centrifuged at 4000 g at 4 °C for 10 min and a low-speed su-
pernatant fraction (S1) was used for measurement of the biochemical
parameters: thiobarbituric acid-reactive species (TBARS), non protein
thiols (NPSH), catalase (CAT) and glutathione S-transferase (GST).
Plasma aspartate (AST) and alanine aminotransferase (ALT) activi-
ties, used as biochemical markers for the early acute hepatic damage,
were determined by the colorimetric method of Reitman and Frankel
(1957). Renal function was analyzed by determining plasma urea
(Mackay and Mackay, 1927) and creatinine levels (Jaffe, 1986). All as-
says were carried out using commercial kits (LABTEST, Diagnostic S.A.
Minas Gerais, Brazil).
Lipid peroxidation
Lipid peroxidation was estimated by measuring TBARS assay,
according to themethod by Ohkawa et al. (1979). The low-speed super-
natant (S1) of liver, kidney, cerebral cortex and hippocampus, were in-
cubated with 0.8% thiobarbituric acid (TBA), acetic acid buffer pH 3.4
and 8.1% sodium dodecyl sulphate at 95 °C for 2 h. The amount of
TBARS produced was measured at 532 nm, using MDA as a biomarker
of lipid peroxidation. TBARS levels are expressed as nmol of MDA/mg
protein.
Non-protein thiols (NPSH) determination
To evaluate the non-enzymatic antioxidant defenses, the NPSH
levels in liver, kidney, cerebral cortex and hippocampus samples were
determined according to the method proposed by Ellman (1959) with
some modiﬁcations. An aliquot S1 were precipitated with TCA (10%)
and subsequently centrifuged at 3000 ×g for 10 min. After the centrifu-
gation, the protein pellet was discarded and free –SH groups were
determined in the clear supernatant. An aliquot of supernatant was
added in 1 M potassium phosphate buffer, pH 7.4, and 10 mM 5,5-
dithio-bis(2-nitrobenzoic acid) (DTNB). The color reaction wasmeasured at 412 nm. NPSH levels were expressed as nmol NPSH/mg
protein.
Catalase (CAT) activity
Catalase activity was assayed spectrophotometrically by a method
proposed byAebi (1984), which involvesmonitoring the disappearance
of H2O2 in the homogenate at 240 nm. Enzymatic reactionwas initiated
by adding an aliquot of 20 μl of S1 of liver, kidney, cerebral cortex and
hippocampus and the substrate (H2O2) to a concentration of 0.3 mM
in a medium containing 50 mM phosphate buffer, pH 7.0. One unit of
enzyme was deﬁned as the amount of enzyme required for monitoring
the disappearance of H2O2. The enzymatic activity was expressed in
units (U)/mg protein (1U decomposes 1 mmol of H2O2/min at pH 7 at
25 °C).
Glutathione S-transferase (GST) activity
GST activity was assayed spectrophotometrically at 340 nm by the
method of Habig et al. (1974). The reaction mixture contained an ali-
quot S1 of liver, kidney, cerebral cortex and hippocampus, 0.1 M potas-
siumphosphate buffer pH 7.4, 100 mMglutathione (GSH) and 100 mM
CDNB, which was used as substrate. The enzymatic activity was
expressed as nmol CDNB conjugated/min/mg of protein.
Protein determination
Protein content was measured colorimetrically by the method of
Bradford (1976), and bovine serum albumin (1 mg/ml) was used as
standard.
Statistical analysis
The results are expressed as themean ± standard error of the mean
(SEM). Statistical analysis was performed using a one-way analysis of
variance (ANOVA) followed by Newman–Keuls (acute toxicity, bio-
chemical parameters and monoamine neurotransmitter levels and
their metabolites) or two-way ANOVA followed by Bonferroni's post
hoc test (behavioral tests). The level of signiﬁcance was set at p b 0.05.
The statistical analysis was performed using the software GraphPad
Prism version 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Effect of the Se-TZ on the immobility time in the TST and locomotor and
exploratory activity in the OFT
In order to investigate the interval time that the Se-TZ achieves the
best performance in TST, a time–course curvewas carried out. Fig. 2A il-
lustrates the immobility time after the administration of the Se-TZ
(50 mg/kg, p.o.), that was able to produce an antidepressant-like effect
in the TST. One-way ANOVA revealed a signiﬁcant effect of the Se-TZ in
the TST [F(4, 33) = 16.33; p b 0.001]. Moreover, post hoc analyses
showed that the Se-TZ exhibits a similar performance in the time inter-
vals (30 and 60 min), and the antidepressant-like effect remained sig-
niﬁcant up to 120 min, however this effect was abolished in 240 min.
Considering these data, all experiments were performed using 30 min
as interval time to investigate the effect of the Se-TZ and its mechanism
of action.
The results illustrated in Fig. 2B show that the Se-TZ or the conven-
tional antidepressants (used as positive controls),ﬂuoxetine (32 mg/kg,
p.o., a serotonin reuptake inhibitor) or imipramine (15 mg/kg, p.o., a tri-
cyclic antidepressant) given by oral route, 30 min before the TST, de-
creased the immobility time. One-way ANOVA revealed a signiﬁcant
effect of the Se-TZ in the TST [F(4, 24) = 11.39; p b 0.001]. Post hoc
analysis indicated a signiﬁcant decrease in the immobility time elicited
by the administration of the Se-TZ at doses of 5, 25 and 50 mg/kg (p.o.)
in the TST.
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Fig. 2. Effect of acute administration of Se-TZ, ﬂuoxetine and imipramine on immobility
time in the TST in mice. Time–course curve of Se-TZ (50 mg/kg, p.o.; panel A) adminis-
tered 30, 60, 120 and 240 min before the TST. Dose–response curve of Se-TZ (1, 5, 25
and 50 mg/kg, p.o.; panel B) administered 30 min before the TST. Fluoxetine (32 mg/kg,
p.o.) and imipramine (15 mg/kg, p.o.), were used as positive controls and they were ad-
ministered 30 minbefore theTST. The valueswere analyzed byone-wayANOVA, followed
by the Newman–Keuls, each value is expressed as the means ± S.E.M. (n = 6–8 mice in
each group). Asterisks represent signiﬁcant effect (*p b 0.05; **p b 0.01; ***p b 0.001)
when compared with the respective control.
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Fig. 3. Effect of pre-treatment with prazosin (1 mg/kg, i.p.; panel A), yohimbine (1 mg/kg,
i.p.; panel B) and propranolol (2 mg/kg, i.p.; panel C) on the immobility time of Se-TZ
(25 mg/kg, p.o.) in the TST inmice. The valueswere analyzed by two-way ANOVA follow-
ed by Bonferroni's test, each value is expressed as the means ± S.E.M. (n = 6–8 mice in
each group). Asterisks represent signiﬁcant effect (***p b 0.001) when compared with
the respective vehicle-treated control.
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nists, at all doses tested, did not produce any change in the number of
crossings and rearing in the mice OFT, indicating that a confounding
locomotor and exploratory activity impairment can be discarded in
the antidepressant-like effect observed in the TST (data not shown).
Investigation of the mechanisms underlying the antidepressant-like effect
of the Se-TZ in the TST
With the purpose of investigating the mechanisms underlying the
antidepressant-like effect of Se-TZ in the TST, mice were pre-treated
with prazosin, yohimbine or propranolol (involvement of the noradren-
ergic system); SCH23390 or sulpiride (involvement of thedopaminergic
system) and methysergide (involvement of the serotonergic system).
The results depicted in Fig. 3A show that the pre-treatment of
mice with prazosin (1 mg/kg, i.p., an α1-adrenoceptor antagonist),
did not antagonize the reduction in immobility time elicited by Se-
TZ (25 mg/kg, p.o.) in the TST. Two-way ANOVA revealed a main effect
of treatment Se-TZ (F(1, 18) = 61.09; p b 0.001), but not of the pre-
treatment with prazosin (F(1, 18) = 5.80; p = 0.027) and pre-treatment × treatment interaction (prazosin × Se-TZ) (F(1, 18) =
0.02; p = 0.897). Fig. 3B shows that the pre-treatment of micewith yo-
himbine (1 mg/kg, i.p., anα2-adrenoceptor antagonist), did not reverse
the reduction in immobility time elicited by Se-TZ (25 mg/kg, p.o.) in
the TST. Two-way ANOVA revealed a main effect of treatment Se-TZ
(F(1, 16) = 62.28; p b 0.001), but not of the pre-treatment with
yohimbine (F(1, 16) = 0.97; p = 0.338) and pre-treatment ×
treatment interaction (yohimbine × Se-TZ) (F(1, 16) = 0.11; p =
0.747). Fig. 3C shows that the pre-treatment of mice with propranolol
(2 mg/kg, i.p., aβ-adrenoceptor antagonist), did not block the reduction
in immobility time elicited by Se-TZ (25 mg/kg, p.o.) in the TST. Two-
Vehicle Se-TZ
0
100
200
300
Vehicle Methysergide
***
# #
Im
m
ob
ili
ty
 ti
m
e 
(s)
Fig. 5. Effect of pre-treatmentwithmethysergide (2 mg/kg, s.c.) on immobility time of Se-
TZ (25 mg/kg, p.o.) in the TST in mice. The values were analyzed by two-way ANOVA
followed by Bonferroni's test, each value is expressed as the means ± S.E.M. (n = 6–8
mice in each group). Asterisks represent signiﬁcant effect (***p b 0.001) when compared
with the respective vehicle-treated control. (##p b 0.001) as compared with Se-TZ alone.
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38.82; p b 0.001), but not of the pre-treatment with propranolol
(F(1, 16) = 1.51; p = 0.236) and pre-treatment × treatment interac-
tion (propranolol × Se-TZ) (F(1, 16) = 0.77; p = 0.392).
Fig. 4A shows that the pre-treatment of mice with SCH23390
(0.05 mg/kg, s.c., a selective dopamine D1 receptor antagonist), pre-
vents the effect of Se-TZ (25 mg/kg, p.o.) in the TST. Two-way ANOVA
revealed signiﬁcant differences of treatment Se-TZ (F(1, 16) = 23.25;
p b 0.002), pre-treatment with SCH23390 (F(1, 16) = 28.35;
p b 0.001) and pre-treatment × treatment interaction (SCH23390 ×
Se-TZ) (F(1, 16) = 12.08; p b 0.003). Fig. 4B shows that the pre-
treatment of mice with sulpiride (50 mg/kg, i.p., a selective dopamine
D2 receptor antagonist), was effective in reversing the effect of Se-TZ
(25 mg/kg, p.o.) in the TST. Two-wayANOVA revealed signiﬁcant differ-
ences of treatment Se-TZ (F(1, 16) = 7.44; p b 0.015), pre-treatment
with sulpiride (F(1, 16) = 10.33; p b 0.005) and pre-treatment ×
treatment interaction (sulpiride × Se-TZ) (F(1, 16) = 5.83; p b 0.028).
Fig. 5 shows that the pre-treatment of mice with methysergide
(2 mg/kg, s.c., a non-selective serotoninergic receptor antagonist), re-
versed the effect of Se-TZ (25 mg/kg, p.o.) in the TST. Two-way
ANOVA revealed signiﬁcant differences of treatment Se-TZ (F(1,
16) = 11.80; p b 0.004), pre-treatment with methysergide (F(1,
16) = 20.84; p b 0.004) and pre-treatment × treatment interaction
(methysergide × Se-TZ) (F(1, 16) = 19.38; p b 0.005).Vehicle Se-TZ
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Fig. 4. Effect of pre-treatment with SCH23390 (0.05 mg/kg, s.c.; panel A) and sulpiride
(50 mg/kg, i.p.; panel B) on immobility time of Se-TZ (25 mg/kg, p.o.) in the TST in
mice. The values were analyzed by two-way ANOVA followed by Bonferroni's test, each
value is expressed as the means ± S.E.M. (n = 6–8 mice in each group). Asterisks repre-
sent signiﬁcant effect (***p b 0.001) when compared with the respective vehicle-treated
control. (#p b 0.01; ##p b 0.001) as compared with Se-TZ alone.Effects of Se-TZ on monoamine neurotransmitter levels and their
metabolites
The levels of monoamine neurotransmitters and their metabolites
detected in the cerebral cortex and hippocampus were summarized in
Table 1. We observed that Se-TZ (25 mg/kg, p.o.) induced a signiﬁcant
increase in cortical and hippocampal serotonin levels, whereas 5-HIAA
levels were signiﬁcantly decreased in the cerebral cortex and sugges-
tively increased in the hippocampus. Furthermore, the 5-HIAA/
serotonin ratio diminished in these two brain sections examined. Simi-
larly, we also detected an increase in dopamine level in the cerebral cor-
tex and hippocampus, whereas decreases in DOPAC levels in the
cerebral cortex, although, levels were not signiﬁcantly altered in the
hippocampus. The ratios of DOPAC/dopamine were signiﬁcantly re-
duced in these two brain sections examined. Moreover, there were no
alterations in noradrenaline or MHPG levels or in the MHPG/noradren-
aline ratio in any of the brain regions examined.
Acute toxicity and biochemical parameters
Oral administration of Se-TZ, at all doses tested (1–50 mg/kg), did
not alter plasma AST or ALT activities, or the urea and creatinine levels
when compared to the control group (Table 2).
The TBARS levels, a measure of lipid peroxidation, were not changed
in the liver, kidney, cerebral cortex or hippocampus of the treated mice
after oral exposure to Se-TZwhen compared to the control group, as can
be seen in Table 3. Furthermore, in order to evaluate non-enzymatic
antioxidant defenses, we measured NPSH levels. Statistical analysesTable 1
The levels of monoamine neurotransmitters and their metabolite (ng/g tissue) in cerebral
cortex and hippocampus of mice after acute treatment with Se-TZ (25 mg/kg).
Group Cerebral cortex Hippocampus
Control Se-TZ Control Se-TZ
NE 575.8 ± 13.38 557.5 ± 18.82 557.0 ± 14.40 556.8 ± 14.96
MHPG 277.8 ± 9.42 269.8 ± 10.53 554.3 ± 21.14 535.3 ± 30.71
MHPG/NE 0.48 ± 0.01 0.49 ± 0.02 1.0 ± 0.04 0.95 ± 0.05
5-HT 445.0 ± 18.71 590.0 ± 16.19*** 650.0 ± 12.46 835.8 ± 21.71***
5-HIAA 350.5 ± 10.99 278.0 ± 13.69** 618.8 ± 8.28 710.5 ± 14.9**
5-HIAA/5-HT 0.77 ± 0.06 0.47 ± 0.03*** 1.03 ± 0.03 0.84 ± 0.01*
DA 714.3 ± 13.03 855.5 ± 30.26*** 614.8 ± 9.13 746.5 ± 27.65***
DOPAC 603.5 ± 12.9 530.3 ± 13.91** 643.5 ± 14.62 624.3 ± 10.14
DOPAC/DA 0.84 ± 0.02 0.62 ± 0.02*** 1.05 ± 0.04 0.85 ± 0.03*
The values were analyzed by one-way ANOVA, followed by the Newman–Keuls, each
value is expressed as the mean ± S.E.M (n = 5). Asterisks represent signiﬁcant effect
(*p b 0.05; **p b 0.01; ***p b 0.001) when compared with the respective control.
398 F. Donato et al. / Life Sciences 93 (2013) 393–400revealed that, at the dose of Se-TZ (50 mg/kg, p.o.), levels were also not
altered in the kidney, cerebral cortex or hippocampus. However, there
was an increase in NPSH levels in hepatic tissue (Table 3).
As can be observed in Table 4 after oral exposure to Se-TZ, the results
showed signiﬁcantly increased CAT activity at all doses in the cerebral
cortex and at doses (25 and 50 mg/kg) in the hippocampus. Similarly,
oral exposure to Se-TZ (5, 25 and 50 mg/kg) increased in GST activity
in the cerebral cortex. However, CAT and GST activities in the liver and
kidney are not altered after treatment with Se-TZ at all doses (Table 4).
Discussion
In the present study, we demonstrated that Se-TZ administered by
oral route produces a signiﬁcant antidepressant-like effect in the TST
in mice. Additionally, the locomotor and exploratory activity was not
changed. Moreover, an involvement of serotonergic (serotonergic re-
ceptors) and dopaminergic (D1 and D2 receptors) systems in the
antidepressant-like effect of Se-TZ was evidenced, but not with norad-
renergic (α1, α2 and β) system. Determination of levels of monoamine
neurotransmitters and their metabolites detected in the cerebral cortex
and hippocampus, cooperate with results obtained previously. Further-
more, it can be suggested that the Se-TZ demonstrated antioxidant ac-
tivity, by increased antioxidant enzymes, such as CAT and GST,
without causing acute toxicity in biochemical hepatic and renal damage
markers.
This study shows that the acute administration of Se-TZ by oral
route is effective to produce a signiﬁcant antidepressant-like re-
sponse in the TST in mice. Moreover, it was noteworthy that the
antidepressant-like effect produced by Se-TZ was similar to the ef-
fect produced by the classical antidepressants ﬂuoxetine and imipra-
mine in the TST. The TST is widely used as animal model reported to
be a predictive test of antidepressant action sensitive to the acute
administration of antidepressant drugs (Steru et al., 1985). In accor-
dance with these results, other organoselenium-containing hetero-
cycle compounds also have antidepressant-like effect (Gai et al.,
2012; Gay et al., 2010; Posser et al., 2009). Monoamine neurotrans-
mitters, such as noradrenaline, dopamine and serotonin, are be-
lieved to be involved in depressive disorders and play important
roles in mediating behavioral effects of antidepressant drugs
(Elhwuegi, 2004).
The dopaminergic system is also an important target implicated in
the regulation of depression (Klimek et al., 2002). DA has many func-
tions in the brain, including important roles in behavior and cognition,
punishment and reward, sleep, mood, attention and learning (Dunlop
and Nemeroff, 2007). In our study, the pre-treatment of mice with
SCH23390 or sulpiride, selective dopamine D1 and D2 receptor antago-
nists, respectively, was able to reverse the antidepressant-like effect of
Se-TZ. The results presented here indicate that the dopaminergic sys-
tem appears to be implicated in the antidepressant-like effect of Se-TZ
in the TST. This result is somewhat in agreement with previous studies
that show that SCH23390 and sulpiride are able to prevent the
antidepressant-like effect of several putative antidepressant agents in
the FST, such as other organoselenium compounds (Oliveira et al.,Table 2
Effect of acute treatment with Se-TZ administered orally on biochemical parameters in
mice.
Dose (mg/kg) AST (U/l) ALT (U/l) Urea (mg/dl) Creatinine (mg/dl)
Control 124.2 ± 6.04 44.03 ± 6.18 46.19 ± 4.3 0.13 ± 0.01
1 131.6 ± 12.01 34.05 ± 6.71 46.32 ± 10.9 0.13 ± 0.01
5 124.8 ± 8.18 33.75 ± 4.83 40.56 ± 13.06 0.15 ± 0.02
25 164.9 ± 10.67 44.32 ± 6.77 19.53 ± 2.53 0.16 ± 0.01
50 124.7 ± 6.02 36.69 ± 5.01 24.95 ± 4.36 0.15 ± 0.02
The values were analyzed by one-way ANOVA, followed by the Newman–Keuls, each
value is expressed as the mean ± S.E.M (n = 6–8).2012; Posser et al., 2009). In this context, classical antidepressant
drug, imipramine (a tricyclic antidepressant), has involvement of dopa-
mineD1 and D2 receptors in themechanism of action in the TST (Hirano
et al., 2007).
Since serotonin is the main neurotransmitter involved in the cogni-
tive functions, it has been proposed that an increase in serotonergic
neurotransmission might counteract the cognitive impairment includ-
ing in memory and learning which is considered a core feature of
major depressive disorder (Baune et al., 2010; Haider et al., 2007). In
this study, the anti-immobility effect of Se-TZ was abolished when
micewere pre-treatedwithmethysergide (a non-selective serotoniner-
gic receptor antagonist) thereby conﬁrming the possible involvement of
the serotonergic system in the antidepressant-like effect. Similarly, it
has been shown that the effects of some antidepressants are prevented
by the concurrent administration of a serotoninergic receptor antago-
nist, by increasing extracellular serotonin after blockade of the seroto-
nin transporter (O'Leary et al., 2007).
Depression is also associatedwith a hypofunction of the noradrener-
gic system (Elhwuegi, 2004). In fact, some antidepressants such as
mazindol, reboxetine and mirtazapine act by increasing the synaptic
availability of noradrenaline (Nikiforuk et al., 2010; Scates and
Doraiswamy, 2000). In our study, the decrease in the immobility time
elicited by Se-TZ was not reversed by prazosin (anα1-adrenoceptor an-
tagonist), yohimbine (an α2-adrenoceptor antagonist) or propranolol
(a β-adrenoceptor antagonist), suggesting that noradrenergic system
may not be involved in antidepressant-like effects of Se-TZ. Similar re-
sults was reported in previous studies with other organoselenium com-
pounds, that the antidepressant-like effect was not dependent on the
stimulation of noradrenergic system (Gerzson et al., 2012; Jesse et al.,
2010). The doses used to block the noradrenergic agents, were based
on studies of literature and the curve of agonists/antagonists of each re-
ceptor was performed in our laboratory in previous experiments (Jesse
et al., 2010; Savegnago et al., 2007); however, no positive control was
used in this experiment.
In addition, to support the hypothesis that the antidepressant-like
effect of Se-TZ is mediated by the increase of serotonin and dopamine
levels, the effect of Se-TZ on the monoamine neurotransmitters and
their metabolites in mice brain was studied. In our study, we focused
on two brain structures, the cerebral cortex and hippocampus, which
are both critically involved in the regulation of depression related emo-
tion,motivation, learning andmemory (Mao et al., 2011). In the present
study, Se-TZ, at a dose (25 mg/kg, p.o.) and time (2 h before testing)
maximum that exert an antidepressant-like effect, Se-TZ signiﬁcantly
enhanced serotonin and dopamine levels in the cerebral cortex and hip-
pocampus, additionally, a decrease in 5-HIAA and DOPAC levels were
detected in the cerebral cortex. Also, there was an increase in 5-HIAA
levels in the hippocampus of Se-TZ treated mice. However, noradrena-
line and MHPG levels were not altered in any brain region, suggesting
that the antidepressant-like effect of Se-TZ in the TST appears to be me-
diated by dopaminergic and serotoninergic neurotransmitters but not
by noradrenaline in the mice brain.
The ratio of the major metabolite to the corresponding monoamine
is commonly used as an index of monoamine turnover (Kitanaka et al.,
2006). As the ratio of the neurotransmitter compared to its metabolites
(turnover) can be used as an index of neurotransmittermetabolism, the
reduction of turnover indicates a slowdown in the metabolism of neu-
rotransmitters. In this study, Se-TZ induced a decreased turnover in
DOPAC/dopamine and 5-HIAA/serotonin in all of the brain structures
examined, indicating a reduction in dopamine and serotonin metabo-
lism. Conversely, NE turnover was not affected in the two brain areas
analyzed. These results strongly suggest that Se-TZ can cause dopami-
nergic and serotoninergic activation in speciﬁc regions of the brain,
and consequently, elevating the availability of these neurotransmitters,
which is consistent with the behavioral changes exhibited in TST. Thus,
the current study conﬁrmed that the dopaminergic and serotonergic
systems might be implicated in the antidepressant-like effect of Se-TZ.
Table 3
Effect of acute treatment with Se-TZ on lipid peroxidation and NPSH levels in the liver, kidney, cerebral cortex and hippocampus of mice.
Dose (mg/kg) TBAR'S (nmol MDA/mg of protein) NPSH (nmol NPSH/mg of protein)
Liver Kidney Cortex Hippocampus Liver Kidney Cortex Hippocampus
Control 9.76 ± 0.41 16.23 ± 1.38 30.08 ± 1.87 32.58 ± 1.82 18.18 ± 1.3 46.98 ± 2.87 4.58 ± 0.25 4.71 ± 0.33
1 11.36 ± 1.06 15.19 ± 1.3 23.44 ± 2.27 27.46 ± 1.85 19.78 ± 4.04 48.48 ± 8.46 4.23 ± 0.71 4.17 ± 0.61
5 11.3 ± 0.46 12.80 ± 1.13 26.61 ± 2.17 27.91 ± 3.63 18.59 ± 1.32 48.72 ± 1.65 5.40 ± 0.65 4.93 ± 0.44
25 11.18 ± 0.63 12.92 ± 1.03 27.26 ± 2.53 28.24 ± 1.95 17.74 ± 3.28 54.63 ± 6.24 6.27 ± 0.64 5.16 ± 0.13
50 11.48 ± 0.36 14.31 ± 1.29 26.87 ± 2.99 26.10 ± 1.75 33.34 ± 1.19** 63.69 ± 7.66 7.04 ± 0.86 4.5 ± 0.22
The valueswere analyzed by one-wayANOVA, followed by the Newman–Keuls, each value is expressed as themean ± S.E.M (n = 6–8). Asterisks represent signiﬁcant effect (**p b 0.01)
when compared with the respective control.
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genesis of major depression. Maes et al. (2000), as well as a growing
number of other investigators (Sarandol et al., 2007; Tsuboi et al.,
2006) have established the co-existence of increased oxidative stress
with symptoms of depression in patients. Several studies provide evi-
dences for the cumulative antioxidant-promoting effects of different
classes of antidepressants, for example, venlafaxine, amitriptyline and
ﬂuoxetine, which may represent a more universal mechanism of action
that not only involves potential target of antidepressant regulation
(Kolla et al., 2005), but also extends to other enzymatic and non-
enzymatic antioxidants. Therefore, antidepressant therapeutic inter-
vention may be associated with the normalization of critical oxidative
processes along with alleviating the depressive symptoms.
Interestingly, our results evidenced an increase of important antiox-
idant enzymes, CAT activity in the hippocampus and cerebral cortex,
and similarly, there increased in GST activity in cerebral cortex,
suggesting the protective effect in response to an acute treatment of
Se-TZ in mice. Moreover, we demonstrated that TBARS levels, were
not changed in the liver, kidney, cerebral cortex or hippocampus of
the treated mice after oral exposure to Se-TZ, demonstrating that this
compound did not cause oxidative stress after acute treatment. Réus
et al. (2010) reported the role of classical antidepressant, such as imip-
ramine that demonstrated after both treatments, acute and chronic in
rats, which improves oxidative stress parameters, through increased
CAT and superoxide dismutase (SOD) activities and decreased MDA
levels in the cerebral cortex and hippocampus. Other studies reported
that the activities of SOD, CAT, GST, glutathione reductase (GR) and
GSH levels increased and yet decreased MDA in the brain samples of
stressed Swiss albino rats by treatment with imipramine, venlafaxine
and ﬂuoxetine, and may thus largely contribute to neuroprotection
(Zaﬁr et al., 2009). Additionally, alpha-tocopherol (vitamin E) adminis-
tration produced antidepressant-like effects in animal models of de-
pression. Along with antidepressant-like effects, long-term treatment
with alpha-tocopherol enhanced antioxidant defenses in the mouse
hippocampus and cerebral cortex, two structures closely implicated in
the pathophysiology of depression (Lobato et al., 2010).
There are studies showing that organoselenium compoundswith an-
tioxidant propertiesmay confer antidepressant-like effects. For example,
ebselen, a substance that mimics the activity of the antioxidant enzyme
GPx (Satoh et al., 2004), decreased immobility time in rodents, an effect
that was dependent on its interaction with the noradrenergic and dopa-
minergic systems (Posser et al., 2009); bis(m-triﬂuoromethyl)-phenylTable 4
Effect of acute treatment with Se-TZ on CAT and GST activities the liver, kidney, cerebral cortex
Dose (mg/kg) Catalase (Ucat/mg protein)
Liver Kidney Cortex Hippocamp
Control 1.45 ± 0.16 3.64 ± 0.39 0.13 ± 0.01 0.27 ± 0.0
1 1.27 ± 0.06 3.52 ± 0.46 0.37 ± 0.06*** 0.30 ± 0.0
5 1.68 ± 0.35 3.27 ± 0.39 0.32 ± 0.03*** 0.54 ± 0.0
25 1.57 ± 0.12 4.06 ± 0.34 0.41 ± 0.04*** 0.83 ± 0.1
50 1.63 ± 0.37 3.11 ± 0.36 0.41 ± 0.03*** 0.78 ± 0.0
The valueswere analyzed byone-wayANOVA, followedby theNewman–Keuls, each value is exp
***p b 0.001) when compared with the respective control.diselenide [(m-CF3-C6H4Se)2], showed antioxidant properties (Prigol
et al., 2009), and antidepressant-like effect involves the modulation of
serotonergic and opioid systems in mice (Brüning et al., 2011); it was
recently shown too that α-(phenylselanyl) acetophenone, showed anti-
oxidant properties and antidepressant-like effects mediated by the sero-
tonergic system, more speciﬁcally, the 5-HT1A receptor subtype in mice
(Gerzson et al., 2012).
Based on the observation above, our data are consistent with a
previous research demonstrating that the presence of antioxidants
may reﬂect the antidepressant properties of a compound. However, it
is not possible to draw more concrete conclusions regarding the roles
of antioxidants in the behavioral responses of mice treated with Se-
TZ; further studies are necessary to conﬁrm and extend these results.
Conclusions
In conclusion, the Se-TZ, a heterocyclic organoselenium compound,
demonstrated antidepressant-like effect mediated, at least partially,
via the central dopaminergic and serotoninergic neurotransmitter
systems. Furthermore, we speculate that Se-TZ might be of interest as
an antioxidant or antidepressant agent for the treatment of depression.
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